End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
- EUR | -.--% | -.--% | -.--% |
03-14 | Abionyx Pharma: to benefit from a 1ME grant from Bpifrance | CF |
03-11 | Abionyx: reduced net loss in 2023 | CF |
Sales 2023 | 4.6M 4.93M 6.77M | Sales 2024 * | 4.6M 4.93M 6.77M | Capitalization | 33.82M 36.24M 49.73M |
---|---|---|---|---|---|
Net income 2023 | -3M -3.22M -4.41M | Net income 2024 * | -6M -6.43M -8.82M | EV / Sales 2023 | 9.02 x |
Net cash position 2023 * | 100K 107K 147K | Net cash position 2024 * | 3.4M 3.64M 5M | EV / Sales 2024 * | 6.61 x |
P/E ratio 2023 * |
-7.5
x | P/E ratio 2024 * |
-7
x | Employees | - |
Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 77.63% |
Managers | Title | Age | Since |
---|---|---|---|
Cyrille Tupin
CEO | Chief Executive Officer | 48 | 06-12-31 |
Director of Finance/CFO | - | 08-04-30 | |
Renee Benghozi
CTO | Chief Tech/Sci/R&D Officer | - | 15-02-08 |
Members of the board | Title | Age | Since |
---|---|---|---|
Olivier Martinez
BRD | Director/Board Member | 54 | - |
Christian Chavy
BRD | Director/Board Member | 75 | 15-02-05 |
Cyrille Tupin
CEO | Chief Executive Officer | 48 | 06-12-31 |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-1.17% | 104B | |
+2.87% | 97.47B | |
+2.13% | 22.25B | |
-14.77% | 21.68B | |
-8.79% | 18.2B | |
-39.98% | 17.02B | |
-13.21% | 16.36B | |
+8.55% | 14.39B | |
+35.75% | 12.37B |